Alessandro Natoni | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killar Cell-Mediated Cytotoxicity	BLOOD	2018
TARGETING SIGLEC-7: A NOVEL IMMUNOTHERAPEUTIC APPROACH TO POTENTIATE THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA	HAEMATOLOGICA	2018
Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study	BLOOD	2018
Engineering CD38 low natural killer cells to transiently express CD16 (f158v) m-RNA enhances the cytotoxic potential of daratumumab against multiple myeloma with minimal NK cell fratricide	HUMAN GENE THERAPY	2018
Combination targeting of sialylation and the proteasome inhibits tumor growth and increases survival in a humanized mouse multiple myeloma model	HEMASPHERE	2018
Targeting siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer cells against multiple myeloma	HEMASPHERE	2018
Novel kinase inhibitors afuresertib and pim447 are active in a predictive myeloma in vivo model, and a crispr genome-wide screening approach identifies biomarkers determining susceptibility	HEMASPHERE	2018
Low dose cyclophosphamide potentiates the anti-myeloma activity of daratumumab through augmentation of macrophage-induced ADCP	HAEMATOLOGICA	2018
Novel kinase inhibitors afuresertib and PIM447 are active alone and in combination with standard therapies, respectively, in a predictive MM in vivo model, and a CRISPR genome-wide screening approach identifies clinically-relevant biomarkers determining susceptibility to these therapeutic strategies	HAEMATOLOGICA	2018
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271	LEUKEMIA	2017
Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP	BLOOD	2017
Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma	BLOOD	2017
Targeting Selectins and Their Ligands in Cancer	FRONTIERS IN ONCOLOGY	2016
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP	BLOOD	2016
A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13)	BLOOD	2016
Targeting the Pim kinases in multiple myeloma	BLOOD CANCER JOURNAL	2015
Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma	BLOOD	2015
E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271	BLOOD	2015